HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults ...
Researchers have created a powerful new cellular model to study rare tumors that are resistant to immunotherapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results